Overslaan en naar de inhoud gaan

 Alle verbonden artikelen

The Benefit of Reactivating p53 under MAPK Inhibition on the Efficacy of Radiotherapy in Melanoma.

Auteurs : Krayem M, Sabbah M, Najem A, Wouters A, Lardon F, Simon S, Sales F, Journe F, Awada A, Ghanem GE, Van Gestel D
Jaar : 2019
Journal : Cancers (Basel)
Volume : 11

Clinical outcomes of laryngopharyngeal reflux treatment: A systematic review and meta-analysis.

Auteurs : Lechien JR, Saussez S, Schindler A, Karkos PD, Hamdan AL, Harmegnies B, De Marrez LG, Finck C, Journe F, Paesmans M, Vaezi MF
Jaar : 2019
Journal : Laryngoscope
Volume : 129
Pagina's : 1174-1187

Involvement of HPV Infection in the Release of Macrophage Migration Inhibitory Factor in Head and Neck Squamous Cell Carcinoma.

Auteurs : Kindt N, Descamps G, Lechien JR, Remmelink M, Colet JM, Wattiez R, Berchem G, Journe F, Saussez S
Jaar : 2019
Journal : J Clin Med
Volume : 8

Age-related changes in the BACH2 and PRDM1 genes in lymphocytes from healthy donors and chronic lymphocytic leukemia patients.

Auteurs : Chi VLD, Garaud S, De Silva P, Thibaud V, Stamatopoulos B, Berehad M, Gu-Trantien C, Krayem M, Duvillier H, Lodewyckx JN, Willard-Gallo K, Sibille C, Bron D
Jaar : 2019
Journal : BMC Cancer
Volume : 19
Pagina's : 81

Role of Macrophage Migration Inhibitory Factor (MIF) in Melanoma.

Auteurs : Soumoy L, Kindt N, Ghanem G, Saussez S, Journe F
Jaar : 2019
Journal : Cancers (Basel)
Volume : 11

Immunohematology Mesenchymal Stromal Cell-based Therapy: From Research to Clinic.

Auteurs : Najar M, Krayem M, Meuleman N, Bron D, Hélène B, Lagneaux L
Jaar : 2018
Journal : Appl Immunohistochem Mol Morphol
Volume : 26(3)
Pagina's : e26-e43

Insights into inflammatory priming of mesenchymal stromal cells: functional biological impacts.

Auteurs : Najar M, Krayem M, Merimi M, Burny A, Meuleman N, Bron D, Raicevic G, Lagneaux L
Jaar : 2018
Journal : Inflamm Res
Volume : 67(6)
Pagina's : 467-477

High infiltration of CD68+ macrophages is associated with poor prognoses of head and neck squamous cell carcinoma patients and is influenced by human papillomavirus.

Auteurs : Seminerio I, Kindt N, Descamps G, Bellier J, Lechien JR, Mat Q, Pottier C, Journe F, Saussez S
Jaar : 2018
Journal : Oncotarget
Volume : 9
Pagina's : 11046-11059

Targeting prohibitin with small molecules to promote melanogenesis and apoptosis in melanoma cells.

Auteurs : Djehal A, Krayem M, Najem A, Hammoud H, Cresteil T, Nebigil CG, Wang D, Yu P, Bentouhami E, Ghanem GE, Désaubry L
Jaar : 2018
Journal : Eur J Med Chem
Volume : 155
Pagina's : 880-888

Acquired resistance to BRAFi reverses senescence-like phenotype in mutant BRAF melanoma.

Auteurs : Krayem M, Najem A, Journe F, Morandini R, Sales F, Awada A, Ghanem GE
Jaar : 2018
Journal : Oncotarget
Volume : 9
Pagina's : 31888-31903

Breast cancer cells and bone marrow mesenchymal stromal cells: a regulated modulation of the breast tumor in the context of immune response.

Auteurs : Najar M, Fayyad-Kazan H, Faour WH, Badran B, Journe F, Lagneaux L
Jaar : 2017
Journal : Inflamm Res
Volume : 66(2)
Pagina's : 129-39

High stromal Foxp3-positive T cell number combined to tumor stage improved prognosis in head and neck squamous cell carcinoma.

Auteurs : Kindt N, Descamps G, Seminerio I, Bellier J, Lechien JR, Mat Q, Pottier C, Delvenne P, Journe F, Saussez S
Jaar : 2017
Journal : Oral Oncol
Volume : 67
Pagina's : 183-191

N-Acetylcysteine breaks resistance to trastuzumab caused by MUC4 overexpression in human HER2 positive BC-bearing nude mice monitored by 89Zr-Trastuzumab and 18F-FDG PET imaging.

Auteurs : Wimana Z, Gebhart G, Guiot T, Vanderlinden B, Larsimont D, Doumont G, Van Simaeys G, Goldman S, Flamen P, Ghanem G
Jaar : 2017
Journal : Oncotarget

Mesenchymal Stromal Cells and Toll-Like Receptor Priming: A Critical Review.

Auteurs : Najar M, Krayem M, Meuleman N, Bron D, Lagneaux L
Jaar : 2017
Journal : Immune Netw
Volume : 17
Pagina's : 89-102

P53 and MITF/Bcl-2 identified as key pathways in the acquired resistance of NRAS-mutant melanoma to MEK inhibition.

Auteurs : Najem A, Krayem M, Salès F, Hussein N, Badran B, Robert C, Awada A, Journe F, Ghanem G
Jaar : 2017
Journal : Eur J Cancer
Volume : 83
Pagina's : 154-165

Role of macrophage migration inhibitory factor in head and neck cancer and novel therapeutic targets: A systematic review.

Auteurs : Lechien JR, Nassri A, Kindt N, Brown DN, Journe F, Saussez S
Jaar : 2017
Journal : Head Neck
Volume : 39(12)
Pagina's : 2573-2584

Combination of galectin-3, CK19 and HBME-1 immunostaining improves the diagnosis of thyroid cancer.

Auteurs : Arcolia V, Journe F, Renaud F, Leteurtre E, Gabius HJ, Remmelink M, Saussez S
Jaar : 2017
Journal : Oncol Lett
Volume : 14
Pagina's : 4183-4189

N-Acetylcysteine breaks resistance to trastuzumab caused by MUC4 overexpression in human HER2 positive BC-bearing nude mice monitored by 89Zr-Trastuzumab and 18F-FDG PET imaging.

Auteurs : Wimana Z, Gebhart G, Guiot T, Vanderlinden B, Larsimont D, Doumont G, Van Simaeys G, Goldman S, Flamen P, Ghanem G
Jaar : 2017
Journal : Oncotarget
Volume : 8(34)
Pagina's : 56185-56198

MNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma.

Auteurs : Zhan Y, Guo J, Yang W, Goncalves C, Rzymski T, Dreas A, Mikulski M, Brzózka K, Golas A, Kong Y, Ma M, Huang F, Huor B, Guo Q, da Silva SD, Torres J, Cai Y, Topisirovic I, Su J, Bijian K, Alaoui-Jamali MA, Huang S, Journe F, Ghanem G, Miller WH Jr, Del Rincón SV
Jaar : 2017
Journal : J Clin Invest
Volume : 127
Pagina's : 4179-4192

New Drug Combination Strategies in Melanoma: Current Status and Future Directions.

Auteurs : Najem A, Krayem M, Perdrix A, Kerger J, Awada A, Journe F, Ghanem G
Jaar : 2017
Journal : Anticancer Res
Volume : 37
Pagina's : 5941-5953